Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF8-ERVK3-1 readthrough is a **naturally occurring readthrough transcript** between the neighboring ZNF8 (zinc finger protein 8) and ERVK3-1 (endogenous retrovirus group K3, member 1) genes on human chromosome 19[1][2][6]. This **long non-coding RNA (lncRNA)** is classified as a **candidate for nonsense-mediated mRNA decay** (NMD), meaning it is not believed to produce a stable protein product[1][6]. No protein coding function, receptor activity, or other typical therapeutic target attributes have been described for this transcript, and it has **no established role in disease, drug interaction, or clinical biomarkers**[1][2][6]. Its classification as a readthrough transcript and lncRNA, rather than a protein, receptor, or enzyme, means it is **not considered a bona fide molecular drug target**. This entry may be only of relevance for bioinformatics annotation, not for therapeutic or biomarker purposes, and is therefore considered **not a true target** in the conventional sense[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNF8-ERVK3-1 readthrough (ZNF8-ERVK3-1).